A recent study from the Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel shows that “ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation.” This study was published in the 6 April 2015 issue of the journal “Nature cell biology” (the number 1 journal in “Cell biology” research with an impact factor of 20.761) by Prof Tzahor E, D’Uva G, and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Regenerating the lost cardiomyocytes in Myocardial patients: Pitavastatin/Livalo, an inhibitor of HMG-CoA reductase and a blood cholesterol lowering drug, increases the expression of ERBB2 and promotes dedifferentiation of cardiomyocytes via down regulation of its target gene
Significance:
Given that: (1) cardiovascular disease is the leading cause of death worldwide; (2) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; and were expected to be doubled by 2015; and (3) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars, there is an urgent need to find a way to induce regeneration of cardiomyocytes that were lost in Myocardial patients.
This study suggests, for the first time, that Pitavastatin/Livalo, by decreasing the expression of its target gene, it may: (1) increase ERBB2 expression; and (2) induce cardiomycyte regeneration. Thus, pharmacological formulations encompassing “Pitavastatin/Livalo or its analogues“ may be used to promote cardiomyocyte regeneration following myocardial infarction.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Regenerating the lost cardiomyocytes in Myocardial patients: Pitavastatin/Livalo, an inhibitor of HMG-CoA reductase and a blood cholesterol lowering drug, increases the expression of ERBB2 and promotes dedifferentiation of cardiomyocytes via down regulation of its target gene, 5/May/2014, 23.57, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
Undisclosed information: How Pitavastatin/Livalo increases the expression of ERBB2/Her2
